Objectives of this review is to conduct an analysis of current data of cardiotoxicity of anticancer drugs and radiation therapy, methods of cardiovascular risk stratification, strategies for primary and secondary cardioprotection, approaches to monitoring and treating.
Data Sources
A comprehensive search was conducted in PubMed/MEDLINE, Web of Science, Scopus. The search strategy combined medical subject headings related to сardio-oncology, antineoplastic agents, cardioprotective strategies. Reference lists of included studies were manually searched for relevant publications.
Data Summary
The review identifies distinct molecular pathways of cardiotoxicity, ranging from oxidative stress and Top2β inhibition in anthracyclines to immune-mediated myocarditis with checkpoint inhibitors and direct fibrotic damage from radiation. Results for standard heart failure medications remain controversial, often demonstrating no protective benefit in large-scale trials. While baseline risk stratification using biomarkers and advanced imaging methods is essential, current pharmacological interventions show significant heterogeneity in efficacy. Emerging non-pharmacological strategies, particularly structured aerobic exercise and lifestyle modification, show promise in mitigating systemic inflammation and preserving cardiac reserve.
Conclusion
The existing arsenal of methods for the prevention and treatment of CTRCD/CTR-CVT remains very limited and does not meet the scale of the problem. Future progress in cardio-oncology depends on the implementation of multidisciplinary support for oncological patients and the development of personalized, dynamic cardio-risk assessment tools integrated with artificial intelligence with innovative cardioprotectors. There is an urgent need to intensify fundamental and clinical research aimed at developing innovative cardioprotective agents and personalized approaches to the management of cancer patients.
AlDoughaimMAlSuhebanyNAlZahraniM, et al.Cancer biomarkers and precision oncology: A review of recent trends and innovations. Clin Med Insights Oncol2024; 18: 11795549241298541.
2.
FranklinMRPlateroSSainiKS, et al.Immuno-oncology trends: preclinical models, biomarkers, and clinical development. J Immunother Cancer2022; 10: e003231.
3.
SongCHJeongMInH, et al.Trends in the development of antibody-drug conjugates for cancer therapy. Antibodies2023; 12: 72.
4.
Al HabsiTAlibrahimHAl ManthariU, et al.Trends in stereotactic radiosurgery for meningioma: the top 100 most cited articles. Gulf J Oncolog2024; 1: 66–80.
5.
HuhuleaENHuangLEngS, et al.Artificial intelligence advancements in oncology: a review of current trends and future directions. Biomedicines2025; 13: 51.
6.
ThunyFNaidooJNeilanTG. Cardiovascular complications of immune checkpoint inhibitors for cancer. Eur Heart J2022; 43: 4458–4468.
7.
AmeriPBerteroEMeijersWC. Cancer is a comorbidity of heart failure. Eur Heart J2023; 44: 1133–1135.
8.
LaiT-YHuY-WWangT-H, et al.Association of radiation dose to cardiac substructures with major ischaemic events following breast cancer radiotherapy. Eur Heart J2023; 44: 4796–4807.
9.
LinXMaXZhaoS, et al.Cardiovascular toxicity in antitumor therapy: biological and therapeutic insights. Trends Cancer2024; 10: 920–934.
10.
ShilSKumarPMumbrekarKD. Cancer therapy-induced cardiotoxicity: mechanisms and mitigations. Heart Fail Rev2025; 30: 1075–1092.
11.
MoslehiJJ. Cardio-Oncology: a new clinical frontier and novel platform for cardiovascular investigation. Circulation2024; 150: 513–515.
12.
GeentyPDGregoryATNolanM, et al.Cardio-Oncology—Beyond anthracyclines and ejection fraction. Heart Lung Circ2024; 33: 547–552.
13.
HasnowoLALarkinaMSPlotnikovE, et al.Synthesis, 123I-radiolabeling optimization, and initial preclinical evaluation of novel urea-based PSMA inhibitors with a tributylstannyl prosthetic group in their structures. Int J Mol Sci2023; 24: 12206.
14.
MachulkinAEPetrovSABodenkoV, et al.Synthesis and preclinical evaluation of urea-based prostate-specific membrane antigen-targeted conjugates labeled with 177 lu. ACS Pharmacol Transl Sci2024; 7: 1457–1473.
15.
TangTHuangXZhangG, et al.Advantages of targeting the tumor immune microenvironment over blocking immune checkpoint in cancer immunotherapy. Signal Transduct Target Ther2021; 6: 72.
16.
FuRSunYShengW, et al.Designing multi-targeted agents: an emerging anticancer drug discovery paradigm. Eur J Med Chem2017; 136: 195–211.
17.
AyatiAMoghimiSSalarinejadS, et al.A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. Bioorg Chem2020; 99: 103811.
18.
HerrmannJLópez-FernándezTLyonAR. The year in cardiovascular medicine 2023: the top 10 papers in cardio-oncology. Eur Heart J2024; 45: 2197–2200.
19.
BlaesANohriaAArmenianS, et al.Cardiovascular considerations after cancer therapy. JACC CardioOncol2025; 7: 1–19.
20.
Viñas-MendietaAEGallardo-GrajedaA. López-Fernández T. Cardio-oncology: chances and challenges. Basic Res Cardiol2024; 120: –9.
21.
CreaF. The challenge of cancer therapy-related cardiac dysfunction: facts and perspectives. Eur Heart J2024; 45: 4355–4358.
22.
OmlandTHeckSLGulatiG. The role of cardioprotection in cancer therapy cardiotoxicity. JACC CardioOncol2022; 4: 19–37.
23.
CreaF. Cardio-oncology: a focus on cardiovascular toxicities of cancer therapies and on atrial fibrillation in cancer. Eur Heart J2022; 43: 245–248.
24.
Raisi-EstabraghZMurphyACRamalingamS, et al.Cardiovascular considerations before cancer therapy. JACC CardioOncol2024; 6: 631–654.
25.
LeeJTanSRamkumarS. Challenges in the implementation of cardio-oncology trials: lessons learnt from investigating statins in the prevention of anthracycline cardiotoxicity. Cardio-Oncology2024; 10: 88.
26.
KhouriMGKleinMRVelazquezEJ, et al.Current and emerging modalities for detection of cardiotoxicity in cardio-oncology. Future Cardiol2015; 11: 471–484.
27.
LeongDPWalianySAbdel-QadirH, et al.Cardiovascular considerations during cancer therapy. JACC CardioOncol2024; 6: 815–834.
28.
QiuYJiangPHuangY. Anthracycline-induced cardiotoxicity: mechanisms, monitoring, and prevention. Front Cardiovasc Med2023; 10: 1242596.
29.
CamilliMCipollaCMDentS, et al.Anthracycline cardiotoxicity in adult cancer patients. JACC CardioOncol2024; 6: 655–677.
OunRMoussaYEWheateNJ. The side effects of platinum-based chemotherapy drugs: a review for chemists. Dalton Trans2018; 47: 6645–6653.
32.
RachmaBSavitriMSutantoH. Cardiotoxicity in platinum-based chemotherapy: mechanisms, manifestations, and management. Cancer Pathogenesis and Therapy2025; 3: 101–108.
33.
ZhangLWangYMengW, et al.Cardiac safety analysis of anti-HER2-targeted therapy in early breast cancer. Sci Rep2022; 12: 14312.
34.
FranczykBRyszJŁawińskiJ, et al.Cardiotoxicity of selected vascular endothelial growth factor receptor tyrosine kinase inhibitors in patients with renal cell carcinoma. Biomedicines2023; 11: 81.
35.
KuangHYanQLiZ, et al.Comprehensive analysis of VEGF/VEGFR inhibitor-induced immune-mediated hypertension: integrating pharmacovigilance, clinical data, and preclinical models. Front Immunol2024; 15: 1488853.
36.
TouyzRMLangNNHerrmannJ, et al.Recent advances in hypertension and cardiovascular toxicities with vascular endothelial growth factor inhibition. Hypertension2017; 70: 220–226.
37.
KaddouraRDabdoobWAAhmedK, et al.A practical guide to managing cardiopulmonary toxicities of tyrosine kinase inhibitors in chronic myeloid leukemia. Front Med (Lausanne)2023; 10: 1163137.
38.
BouitbirJAlshaikhaliAPanajatovicM, et al.Mechanisms of cardiotoxicity associated with tyrosine kinase inhibitors in H9c2 cells and mice. European Cardiology Review2020; 15: 33.
39.
IgawaYHamanoHEsumiS, et al.Cardiovascular toxicity risk assessment of tyrosine kinase inhibitors: a pharmacovigilance study using the VigiBase database. Front Pharmacol2024; 15: 1472008.
40.
ZhengYLiuZChenD, et al.The cardiotoxicity risk of immune checkpoint inhibitors compared with chemotherapy: a systematic review and meta-analysis of observational studies. Cardiovasc Toxicol2025; 25: 805–819.
41.
AgostinettoEEigerDLambertiniM, et al.Cardiotoxicity of immune checkpoint inhibitors: a systematic review and meta-analysis of randomised clinical trials. Eur J Cancer2021; 148: 76–91.
42.
PatelRPParikhRGunturuKS, et al.Cardiotoxicity of immune checkpoint inhibitors. Curr Oncol Rep2021; 23: 79.
43.
NielsenDLJuhlCBNielsenOH, et al.Immune checkpoint inhibitor–induced cardiotoxicity. JAMA Oncol2024; 10: 1390.
44.
SharmaAAlexanderGChuJH, et al.Immune checkpoint inhibitors and cardiotoxicity: a comparative meta-analysis of observational studies and randomized controlled trials. J Am Heart Assoc2024; 13(10): e032620.
45.
ZotovaL. Immune checkpoint inhibitors-related myocarditis: a review of reported clinical cases. Diagnostics2023; 13: 1243.
46.
WeiTChengY. The cardiac toxicity of radiotherapy – a review of characteristics, mechanisms, diagnosis, and prevention. Int J Radiat Biol2021; 97: 1333–1340.
47.
KoutroumpakisEDeswalAYusufSW, et al.Radiation-Induced cardiovascular disease: mechanisms, prevention, and treatment. Curr Oncol Rep2022; 24: 543–553.
48.
EllPMartinJMCehicDA, et al.Cardiotoxicity of radiation therapy: mechanisms, management, and mitigation. Curr Treat Options Oncol2021; 22: 70.
49.
PodlesnikarTBerlotBDolencJ, et al.Radiotherapy-Induced Cardiotoxicity: The Role of Multimodality Cardiovascular Imaging. Front Cardiovasc Med2022; 9: 887705.
50.
SiaravasKCKatsourasCSSiokaC. Radiation treatment mechanisms of cardiotoxicity: a systematic review. Int J Mol Sci2023; 24: 6272.
51.
ClearySRosenSDGilbertDC, et al.Cardiovascular health: an important component of cancer survivorship. BMJ Oncology2023; 2: e000090.
52.
WilcoxNSRotzSJMullenM, et al.Sex-Specific cardiovascular risks of cancer and its therapies. Circ Res2022; 130: 632–651.
53.
Fernandez TurizoMJKimEZhangC, et al.Pre-existing cardiovascular disease is associated with an increased risk of cardiovascular events during Bruton tyrosine kinase inhibitor therapy. Oncologist2025; 30(2): oyae229.
54.
ChakrabortySVermaAGargR, et al.Cardiometabolic risk factors associated with type 2 diabetes mellitus: a mechanistic insight. Clin Med Insights Endocrinol Diabetes2023; 16: 11795514231220780.
55.
VondenhoffSSchunkSJNoelsH. Increased cardiovascular risk in patients with chronic kidney disease. Herz2024; 49: 95–104.
56.
ChenSTsengC-H. Dyslipidemia, kidney disease, and cardiovascular disease in diabetic patients. Rev Diabet Stud2013; 10: 88–100.
57.
BleuminkGSSchutAFCSturkenboomMCJM, et al.Genetic polymorphisms and heart failure. Genet Med2004; 6: 465–474.
58.
SakowiczAFendlerWLelonekM, et al.Genetic polymorphisms and the risk of myocardial infarction in patients under 45 years of age. Biochem Genet2013; 51: 230–242.
59.
FedeleFPucciMSeverinoP. Genetic Polymorphisms and Ischemic Heart Disease. Genetic Polymorphisms, InTech2017.
60.
LyonARLópez-FernándezTCouchLS, et al.2022 ESC guidelines on cardio-oncology developed in collaboration with the European hematology association (EHA), the European society for therapeutic radiology and oncology (ESTRO) and the international cardio-oncology society (IC-OS). Eur Heart J2022; 43: 4229–4361.
61.
LeeC-HZhangJ-FYuanKS-P, et al.Risk of cardiotoxicity induced by adjuvant anthracycline-based chemotherapy and radiotherapy in young and old Asian women with breast cancer. Strahlenther Onkol2019; 195: 629–639.
62.
ValiyaveettilDJosephDMalikM. Cardiotoxicity in breast cancer treatment: causes and mitigation. Cancer Treat Res Commun2023; 37: 100760.
63.
Bowen JonesSMarchantTSaundersonC, et al.Moving beyond mean heart dose: the importance of cardiac substructures in radiation therapy toxicity. J Med Imaging Radiat Oncol2024; 68: 974–986.
64.
NoHJGuoFBParkNJ-I, et al.Predicting adverse cardiac events after radiotherapy for locally advanced non–small cell lung cancer. JACC CardioOncol2023; 5: 775–787.
65.
HsiehKHotcaAERunnelsJ, et al.The effects of radiation therapy on the heart: implications for management. Chin Clin Oncol2024; 13: 10–10.
66.
PudilRMuellerCČelutkienėJ, et al.Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the cardio-oncology study group of the heart failure association and the cardio-oncology council of the European Society of Cardiology. Eur J Heart Fail2020; 22: 1966–1983.
67.
ZhangXSunYZhangY, et al.Cardiac biomarkers for the detection and management of cancer therapy-related cardiovascular toxicity. J Cardiovasc Dev Dis2022; 9: 72.
68.
AttanasioUDi SarroETricaricoL, et al.Cardiovascular biomarkers in cardio-oncology: antineoplastic drug cardiotoxicity and beyond. Biomolecules2024; 14: 99.
69.
RasheedRSEl SokkaryHEl AmrosyMZ, et al.Role of myocardial strain imaging by echocardiography for the early detection of anthracyclines-induced cardiotoxicity. J Saudi Heart Assoc2022; 34: 32–40.
70.
SławińskiGHawryszkoMLiżewska-SpringerA, et al.Global longitudinal strain in cardio-oncology: a review. Cancers (Basel)2023; 15: 86.
71.
BurrageMKFerreiraVM. The use of cardiovascular magnetic resonance as an early non-invasive biomarker for cardiotoxicity in cardio-oncology. Cardiovasc Diagn Ther2020; 10: 610–624.
72.
HarriesILiangKWilliamsM, et al.Magnetic resonance imaging to detect cardiovascular effects of cancer therapy. JACC CardioOncol2020; 2: 270–292.
73.
KheraRAsnaniAHKriveJ, et al.Artificial intelligence to enhance precision medicine in cardio-oncology: a scientific statement from the American Heart Association. Circ Genom Precis Med2025; 18(2): e000097.
74.
EchefuGShahRSanchezZ, et al.Artificial intelligence: applications in cardio-oncology and potential impact on racial disparities. American Heart Journal Plus: Cardiology Research and Practice2024; 48: 100479.
75.
ScaliaIGPathangeyGAbdelnabiM, et al.Applications of artificial intelligence for the prediction and diagnosis of cancer therapy-related cardiac dysfunction in oncology patients. Cancers (Basel)2025; 17: 605.
76.
MeessenJMTACardinaleDCiceriF, et al.Circulating biomarkers and cardiac function over 3 years after chemotherapy with anthracyclines: the ICOS-ONE trial. ESC Heart Fail2020; 7: 1452–1466.
77.
LiviLBarlettaGMartellaF, et al.Cardioprotective strategy for patients with nonmetastatic breast cancer who are receiving an anthracycline-based chemotherapy. JAMA Oncol2021; 7: 1544.
78.
AvilaMSAyub-FerreiraSMde Barros WanderleyMR, et al.Carvedilol for prevention of chemotherapy-related cardiotoxicity. J Am Coll Cardiol2018; 71: 2281–2290.
79.
GulatiGHeckSLRøsjøH, et al.Neurohormonal blockade and circulating cardiovascular biomarkers during anthracycline therapy in breast cancer patients: results from the PRADA (prevention of cardiac dysfunction during adjuvant breast cancer therapy). Study. J Am Heart Assoc2017; 6(11): e006513.
80.
GulatiGHeckSLReeAH, et al.Prevention of cardiac dysfunction during adjuvant breast cancer therapy (PRADA): a 2x2 factorial, randomized, placebo-controlled, double-blind clinical trial of candesartan and metoprolol. Eur Heart J2016; 37: 1671–1680.
81.
PituskinEMackeyJRKoshmanS, et al.Multidisciplinary approach to novel therapies in cardio-oncology research (MANTICORE 101–breast): a randomized trial for the prevention of trastuzumab-associated cardiotoxicity. J Clin Oncol2017; 35: 870–877.
82.
NeilanTGQuinagliaTOnoueT, et al.Atorvastatin for anthracycline-associated cardiac dysfunction. JAMA2023; 330: 28.
83.
FerreiraJPPittBZannadF. Mineralocorticoid Receptor Antagonists in Heart Failure: An Update. Circ Heart Fail2024; 17(12): e011629.
84.
AkpekMOzdogruISahinO, et al.Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail2015; 17: 81–89.
85.
van DalenECCaronHNDickinsonHO, et al.Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev2011; 2016(6): CD003917.
86.
SzabóZHornyákLMiskeiM, et al.Two targets, one hit: new anticancer therapeutics to prevent tumorigenesis without cardiotoxicity. Front Pharmacol2021; 11: 569955.
87.
RassafT. Bridging cardiology and oncology in the era of precision medicine. Basic Res Cardiol2025; 120: –2.
88.
KeatsMRGrandySAGiacomantonioN, et al.Exercise to prevent anthr cycline-based cardio-toxicity (EXACT) in individuals with breast or hematological cancers: a feasibility study protocol. Pilot Feasibility Stud2016; 2: 44.
89.
ScottJMThomasSMPeppercornJM, et al.Effects of exercise therapy dosing schedule on impaired cardiorespiratory fitness in patients with primary breast cancer. Circulation2020; 141: 560–570.
90.
PfannenstielKHaywardR. Effects of resistance exercise training on doxorubicin-induced cardiotoxicity. J Cardiovasc Pharmacol2018; 71: 332–339.
91.
PhungphongSKijtawornratAKampaengsriT, et al.Comparison of exercise training and estrogen supplementation on mast cell-mediated doxorubicin-induced cardiotoxicity. American Journal of Physiology-Regulatory, Integrative and Comparative Physiology2020; 318: R829–R842.
92.
AhmadianMDabidi RoshanV. Modulatory effect of aerobic exercise training on doxorubicin-induced cardiotoxicity in rats with different ages. Cardiovasc Toxicol2018; 18: 33–42.
93.
ViraniSADentSBrezden-MasleyC, et al.Canadian Cardiovascular society guidelines for evaluation and management of cardiovascular complications of cancer therapy. Can J Cardiol2016; 32: 831–841.
94.
VargheseSSJohnstonWJEekhoudtCR, et al.Exercise to reduce anthracycline-mediated cardiovascular complications in breast cancer survivors. Current Oncology2021; 28: 4139–4156.
95.
ZamoranoJLGottfridssonCAsteggianoR, et al.The cancer patient and cardiology. Eur J Heart Fail2020; 22: 2290–2309.
96.
ZhangHXieSDengW. Mitophagy in doxorubicin-induced cardiotoxicity: insights into molecular biology and novel therapeutic strategies. Biomolecules2024; 14: 1614.
97.
SolomonADDabralSBrajeshRG, et al.Understanding the mechanisms of chemotherapy-related cardiotoxicity employing hiPSC-derived cardiomyocyte models for drug screening and the identification of genetic and epigenetic variants. Int J Mol Sci2025; 26: 3966.
98.
LiangZHeYHuX. Cardio-Oncology: mechanisms, drug combinations, and reverse cardio-oncology. Int J Mol Sci2022; 23: 10617.
99.
XingMYanFYuS, et al.Efficacy and cardiotoxicity of liposomal doxorubicin-based chemotherapy in advanced breast cancer: a meta-analysis of ten randomized controlled trials. PLoS One2015; 10: e0133569.
100.
TheodoulouMHudisC. Cardiac profiles of liposomal anthracyclines. Cancer2004; 100: 2052–2063.
101.
SmithLACorneliusVRPlummerCJ, et al.Cardiotoxicity of anthracycline agents for the treatment of cancer: systematic review and meta-analysis of randomised controlled trials. BMC Cancer2010; 10: 37.
102.
GeisbergCASawyerDB. Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage. Curr Hypertens Rep2010; 12: 404–410.
103.
NajafiSSadeghiMShajariMR, et al.The comparison of anthracycline-based and non-anthracycline-based regimens in adjuvant chemotherapy of HER2-positive non-metastatic breast cancers. Współczesna Onkologia2018; 22: 108–112.
104.
van DalenECMichielsEMCaronHN, et al.Different anthracycline derivates for reducing cardiotoxicity in cancer patients. In: van DalenEC (eds) Cochrane Database of Systematic Reviews. Chichester, UK: John Wiley & Sons, Ltd, 2010.
105.
ForiniFCanalePNicoliniG, et al.Mitochondria-Targeted drug delivery in cardiovascular disease: a long road to nano-cardio medicine. Pharmaceutics2020; 12: 1122.
106.
MukhomedzyanovAVPlotnikovEVMaslovLN, et al.Mechanisms of the cardioprotective effect of lithium. Bulletin of Siberian Medicine2025; 24: 52–59.
107.
GragnanoFCalabròPDe SioV, et al.Anti-inflammatory therapies for cardiovascular diseases: novel evidence, clinical implications, and future perspectives. G Ital Cardiol (Rome)2022; 23: 938–947.
108.
DaiberAStevenSEulerG, et al.Vascular and cardiac oxidative stress and inflammation as targets for cardioprotection. Curr Pharm Des2021; 27: 2112–2130.
109.
WuQBaiBTianC, et al.The molecular mechanisms of cardiotoxicity induced by HER2, VEGF, and tyrosine kinase inhibitors: an updated review. Cardiovasc Drugs Ther2022; 36: 511–524.
110.
WangZYangYWangN, et al.RIP3 orchestrates oxidative stress and pyroptosis in doxorubicin-induced cardiotoxicity through regulation of AKT/Nrf2 signaling cascade 2024. https://doi.org/10.21203/rs.3.rs-3976154/v1.
111.
AggarwalS. Adverse effects of immuno-oncology drugs—awareness, diagnosis, and management: a literature review of immune-mediated adverse events. Indian J Cancer2019; 56: 10.
112.
ZhouYDingS. Key determinants of immune-mediated adverse reactions to oncology drugs. Cancers (Basel)2023; 15: 5622.
